Minerals Technologies Inc. (MTX) -0.45

Trade MTX
NOW!
Last Trade:53.37Short Ratio:2.50
Last Trade Time:4:02pmDay Range:53.05 - 54.71
Ask:Year Range:30.32 - 57.37
Bid:One Year Target:54.50
Open:54.05Exchange:NYSE
Volume:147649EBITDA:117.2M
Prev. Close:53.82Market Cap:1.001B
50 Day Moving:49.7536Div Yield:0.37
200 day moving:50.9862PE:

Chelsea Therapeutics Reports Findings From Northera 24-Hour Blood Pressure Monitoring Study

Posted on 03/17/10 at 9:03am
Northera Effectively Increases SBP in Patients With Neurogenic Orthostatic Hypotension Patients Showed Mean Diurnal Increase of 8.4 mmHg SBP and Mean Nocturnal Increase of 7.8 mmHg SBP While on Northera CHARLOTTE, N.
Click here to read the rest of the article

Genentech Submits Supplemental Biologics License Application for ACTEMRA® (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis

Posted on 03/16/10 at 12:51pm
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S.
Click here to read the rest of the article

Chelsea Therapeutics to Present at the ROTH 22nd Annual OC Growth Stock Conference on Wednesday, March 17, 2010

Posted on 03/12/10 at 8:33am
CHARLOTTE, N.C., March 12, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd.
Click here to read the rest of the article

Chelsea Therapeutics Reports Fourth Quarter and Full Year 2009 Results

Posted on 03/10/10 at 5:27pm
CHARLOTTE, N.C., March 10, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd.
Click here to read the rest of the article

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2009 Results

Posted on 03/03/10 at 8:33am
CHARLOTTE, N.C., March 3, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd.
Click here to read the rest of the article

Chelsea Therapeutics Announces Advancements in Neurogenic Orthostatic Hypotension Registration Program

Posted on 02/09/10 at 8:33am
FDA Confirms Special Protocol Assessment for Study 301 Protocol for Study 306 Finalized, Study to Begin in the Second Quarter Northera Selected as US Brand Name for Droxidopa in Neurogenic Orthostatic Hypotension CHARLO
Click here to read the rest of the article

Biogen Idec Reports Full Year and Fourth Quarter 2009 Results

Posted on 02/09/10 at 8:19am
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.
Click here to read the rest of the article

Minerals Technologies’ Fourth Quarter Diluted Earnings Per Share Were $0.62, Excluding Special Items; Reported Earnings Were $0.22 Per Share

Posted on 02/05/10 at 6:45am
NEW YORK--(BUSINESS WIRE)-- Minerals Technologies Inc. (NYSE: MTX) today reported net income of $4.1 million, or $0.22 per share, for the fourth quarter 2009, compared with $8.9 million, or $0.47 per share in the third quarter of 2009.
Click here to read the rest of the article